αMHC-CatCh-IRES-lacZ Strain Information Sheet
Common Name: αMHC-CatCh-IRES-lacZ
CHROMusTM designation and lines available: R24:B5
Jackson Stock number: NA
Development: The rhodopsin based effector, CatCh was inserted under control of the αMHC minimal promoter (Addgene 55594). The resulting transgene was injected into the male pronucleus of fertilized oocytes which were then implanted into pseudo pregnant females. Resulting offspring were screened for the presence of the transgene (founders). Colonies were established from each founder and tested for expression.
|# pups born||# founders||# expressers|
Description: The rhodopsin based effector, CatCh is expressed under control of the αMHC promoter, directing expression to cardiomyocytes in the heart. An internal ribosome entry site (IRES) allows for co-expression of lacZ as a visual indicator of expression patterns.
Additional data detailing CatCh activity will be added.
|Primer B107||GGA GAT CTA TGT GTG CGC TAT C|
|Primer B108||CCA GCA GTT CTT CGA CAT CA|
|Expected size of product:||535bp|
94oC 3 minutes
So as to appropriately acknowledge and credit the scientists who have produced the αMHC-CatCh-IRES-lacZ mouse strain, it is expected that you will include these individuals in any publication that is submitted prior to the initial publication of this line from the Kotlikoff laboratory.
Acknowledgement: Please inform us of any publications resulting from the use of this mouse and use the following statement to acknowledge their development:
The mouse strain αMHC-CatCh-IRES-lacZ was developed by CHROMusTM which is supported by the National Heart Lung Blood Institute of the National Institute of Health under award number R24HL120847.